India, Oct. 8 -- Medicus Pharma (MDCX) marked its third anniversary as a public company by highlighting its transformation into a precision oncology-focused biotechnology company and outlining a strategy aimed at building long-term value through advancement of multiple therapeutic programs.
Over the past three years, the company has expanded beyond its original SkinJet program and assembled a portfolio that includes CD228V, an investigational antibody-drug conjugate for cancer, SkinJect for basal cell carcinoma in patients with Gorlin syndrome, and Teverelix, a drug candidate with potential applications in urology and women's health.
Medicus said its approach focuses on acquiring and advancing promising drug candidates that already have s...